Peer Schatz, CEO of Qiagen, tells CNBC they are looking at increasing the outlook for 2013 but will continue to manage the bottom line very actively.
Severin Schwan, CEO of Roche, tells CNBC that 2012 was a very good year for Roche with the company outgrowing their markets in both Pharma and Diagnostics by five and four percent.
Emerging markets, and in particular, Latin America will be the drivers for continued growth, Swiss drug maker Roche told CNBC, even as the company faces price pressures elsewhere.
Eli Lilly said fourth-quarter earnings fell as competition from generic drugs, particularly for Zyprexa, drove revenue lower.
Barbara Ryan, former Deutsche Bank senior pharma analyst, tells CNBC why investing in innovation is critical if pharmaceutical companies are to continue to make money.
Sanofi CEO Christopher Viehbacher tells CNBC why there is potential in the emerging market pharmaceutical space.
It’s also for the cats, the horses and a slew of other animals.
Marc Beer, Aegerion Pharmaceuticals CEO, discusses a drug in the company's portfolio that treats patients with severe cholesterol disorder.
Amgen reports earnings today, and some traders have already chalked up profits in the stock.
Joe Jimenez, CEO of Novartis, tells CNBC that 2012 was a transition year for Novartis with 17 major drug approvals.
Johnson & Johnson reported earnings Tuesday that topped analysts' expectations, though revenue was in line with estimates.
After doing some research, the "Mad Money" host comments on stocks viewers wanted to know about.
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
Making the health care system function better could save $2 trillion on health costs over the next decade, Dr. David Blumenthal, Commonwealth Fund president, told CNBC on Friday.
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
"As a group, biotech is the place to be this year," said," Les Funtleyder, Poliwogg fund manager, discussing where to find attractive health care opportunities in 2013.
What a beautiful sight to behold - the stock chart, that is.
John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses why he expects profits to rise this year despite a wave of patent expirations.
CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.